Prognostic Significance of Growth Factors and the Urokinase-Type Plasminogen Activator System in Pancreatic Ductal Adenocarcinoma

@article{Xue2008PrognosticSO,
  title={Prognostic Significance of Growth Factors and the Urokinase-Type Plasminogen Activator System in Pancreatic Ductal Adenocarcinoma},
  author={Aiqun Xue and Christopher J. Scarlett and Christopher John Jackson and Barry J. Allen and Ross C. Smith},
  journal={Pancreas},
  year={2008},
  volume={36},
  pages={160-167}
}
Objectives: To determine the diagnostic and prognostic significance of growth factors and the urokinase-type plasminogen activator (uPA) system in pancreatic ductal adenocarcinoma (PDAC) using a multigene assay. Methods: Messenger RNA (mRNA) expression of 15 genes from epidermal growth factor receptor, insulin-like growth factor (IGF), and uPA families were measured in 46 PDAC tissue samples using quantitative real-time reverse transcription-polymerase chain reaction. These results were… 
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
TLDR
A role for uPAR as a biomarker to single out higher risk subgroups of patients with pancreatic cancer is suggested, with a significant inverse association between uPAR expression in both neoplastic and stromal cells and overall survival.
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
TLDR
A role for uPAR as a biomarker to single out higher risk subgroups of patients with pancreatic cancer is suggested, with a significant inverse association between uPAR expression in both neoplastic and stromal cells and overall survival.
Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
TLDR
The association of high su PAR levels with poor survival of PCa patients suggests a prognostic impact of suPAR levels in serum of cancer patients.
The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
TLDR
An overview of the current understanding of the uPAS in the pathogenesis and progression of pancreatic cancer is provided, with a focus on PDAC, and a substantial body of evidence that supports the role of UPAS components, including plasminogen receptors, in this disease is summarised.
Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients
TLDR
The results suggest that PAI-1 and uPAR-del4/5 mRNA levels may add prognostic information in STS patients with R0 status and distinguish a subgroup of R0 patients with low PAI/1 and/or low u PAR-del 4/5 values who have a better outcome compared to patients with high marker levels.
Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview
TLDR
The structure of the uPA system, its contribution to cancer progression, and the clinical relevance of uPA family members in cancer diagnosis are summarized and the significance of u PA system in the development of cancer‐targeted therapies is evaluated.
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume
TLDR
High pretreatment PAI-1 plasma levels were found predominantly in M0-stage patients and indicate a favorable prognosis as opposed to OPN where high plasma levels are associated with poor survival and metastasis, and support the notion of an antidromic prognostic impact of OPN andPAI- 1 plasma levels in the RT of advanced NSCLC.
CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients
The capillary morphogenesis gene 2 (CMG2), also known as the anthrax toxin receptor 2 (ANTXR2), is a transmembrane protein putatively involved in extracellular matrix (ECM) adhesion and tissue
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
TLDR
For the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1.
...
...

References

SHOWING 1-10 OF 43 REFERENCES
High Expression of Plasminogen Activator Inhibitor-2 (PAI-2) is a Predictor of Improved Survival in Patients with Pancreatic Adenocarcinoma
TLDR
It is demonstrated that it is plasminogen activator inhibitor type 2 (PAI-2), which is the most significant factor of the uPA / PAI system that predicts survival independently in patients with pancreatic cancer both at a molecular and protein level.
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
TLDR
The data suggest that uPA and uPAR may serve as prognostic markers in human pancreatic cancers and that the marked overexpression of both factors may create an environment that enables pancreatic cancer cells to invade surrounding tissues.
Significant overexpression of urokinase‐type plasminogen activator in pancreatic adenocarcinoma using real‐time quantitative reverse transcription polymerase chain reaction
TLDR
The aims of this study were to analyze uPA mRNA expression in pancreatic cancer and to correlate this to the expression of uPA protein and to the stage of the disease.
Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
TLDR
Through the analysis by ROC curve, serum PDGF-BB was the most valuable marker, and its sensitivity was the highest among the nine indices, and the markers with the highest specificity were TIMP-1mRNA and TIMP/MMP- 1mRNA in PBMCs.
Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder
TLDR
MMP2 is a statistically significant marker in blood plasma for bladder cancer detection with an increased diagnostic value in combination with MMP9 and TIMP1, showing that the highest sensitivities and specificities are not obtained by testing each marker alone.
Growth Factors and Cytokines in Pancreatic Carcinogenesis
TLDR
This review focuses on two families of growth factors and growth factor receptors which are representative for the molecular alterations observed in pancreatic cancer: the transforming growth factor‐β superfamily of serine‐threonine kinase receptors and their ligands and the epidermal growth factor receptor family and theirligands.
Assessment of HER-2 Status in Pancreatic Adenocarcinoma: Correlation of Immunohistochemistry, Quantitative Real-Time RT-PCR, and FISH With Aneuploidy and Survival
HER-2 is a transmembrane growth factor receptor recognized in overexpression as an independent adverse prognostic factor in several cancers. This study measured HER-2 overexpression in pancreatic
Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression.
TLDR
The data indicate that a significant proportion of human pancreatic cancers overexpress erbB-3, and that erb B-3 may contribute to disease progression in this disorder.
Cripto, a member of the epidermal growth factor family, is over‐expressed in human pancreatic cancer and chronic pancreatitis
TLDR
Cripto expression may contribute to disease progression in pancreatic cancer, and implicate cripto in the histopathological alterations that occur in the pancreas both in cancer and in CP.
Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
TLDR
Targeting the plasmin(ogen) cascade may provide a new insight into molecular target therapy based on anti-invasion and anti-metastasis for pancreatic cancer.
...
...